

OPTIMISED AMOXICILLIN/CLAVULANIC ACID DOSING IN PATIENTS ON CHRONIC HIGH-FLUX HAEMODIALYSIS

Kelly De Schuyter¹, Pieter J Colin², Floris Vanommelaeghe¹, Sigurd Delanghe¹, Pieter De Cock³, Peter De Paepe⁴, Wim Van Biesen¹, Sunny Eloot¹

¹Department of Nephrology, Ghent University Hospital, Belgium ²Department of Anesthesiology, University Medical Center Groningen, University of Groningen, The Netherlands ³Department of Pharmacy and Heymans Institute of Pharmacology, Ghent University Hospital, Belgium ⁴Heymans Institute of Pharmacology, Ghent University Hospital, Belgium

Background

Amoxicillin/clavulanic acid (AMC) is frequently prescribed to haemodialysis patients, using empirical dosing regimens. The elimination pathway of both compounds differs, making dosing recommendations in end-stage kidney disease challenging.

Pharmacokinetic data of AMC in this patient population are scarce.


The study aim was to optimise dosing regimens of AMC in patients on chronic high-flux haemodialysis.

Methods

- Monocentric prospective observational study including 26 patients on high-flux haemodialysis, receiving different per oral (p.o.) and intravenous (iv) AMC dosing.
- Blood sampling inter- and intradialytic (n=247) to measure concentrations of amoxicillin (AMX) and clavulanic acid (CLA).
- Development of a population pharmacokinetic (PK) model using non-linear mixed effects fitting the observed time-concentration data. Different covariates were added in a stepwise fashion and, if improving the model, were retained.
- Monte Carlo simulations to simulate different dosing strategies over 1 week. The PK/pharmacodynamic (PD) target of AMX was set at 50%t>MIC=8mg/L. For CLA no PK/PD target is established, thus only occurrence of accumulation was studied.

Results

Measured concentration data for both compounds were best fitted by a two-compartmental model with between-subject variability for distribution volume of central compartment (V_1), total body clearance (CL) and dialysis extraction ratio (ER).



ER was high, 74% and 78% for, respectively, AMX and CLA.

Within an individual patient, estimates for V_1 and ER were highly correlated.

CONCLUSION: We propose a dosing strategy of p.o. 500mg/125mg q8h or iv 500mg/100mg q8h after an iv loading dose of 1000mg/200mg to achieve adequate exposure of CLA while minimising AMX accumulation. Considering high dialyser clearance, dosing should be scheduled post-dialysis.

For AMX, residual diuresis and blood flow were kept as covariates, and residual diuresis was associated with CL ($p=0.027$), which was 12mL/min and 22mL/min for a residual diuresis of respectively <500mL/24h and ≥ 500 mL/24h.

AMX

$$CL (mL \min^{-1}) = \begin{cases} 12.1 (18) \cdot e^{\omega_2} & \text{Urine volume (mL 24h}^{-1}) < 500 \\ 21.5 (17) \cdot e^{\omega_2} & \text{Urine volume (mL 24h}^{-1}) > 500 \end{cases}$$

$$V1 (L) = 11.3 (12) \cdot e^{\omega_1}$$

$$ER (\%) = \frac{e^{1.96 (12) - 0.488 (25) \frac{FLOW (mL \min^{-1}) - 115}{100}}}{1 + e^{1.96 (12) - 0.488 (25) \frac{FLOW (mL \min^{-1}) - 115}{100}}} \cdot e^{\omega_3}$$

$$V2 (L) = 12.5 (7.0)$$

$$Q2 (mL \min^{-1}) = 180 (27)$$

CLA

$$CL (mL \min^{-1}) = 64.4 (21) \cdot e^{\omega_4}$$

$$V1 (L) = 16.2 (14) \cdot e^{\omega_1}$$


$$ER (\%) = \frac{e^{1.29 (17)}}{1 + e^{1.29 (17)}} \cdot e^{\omega_3}$$

$$V2 (L) = 7.35 (26)$$

$$Q2 (mL \min^{-1}) = 66.7 (67)$$

All simulated AMX dosing regimens achieved adequate PD target attainment.


Accumulation of AMX was observed in all simulations.



all with administration post HD

A: 500mg/125mg p.o. q24h (plus 500mg/125mg during HD); B: 500mg/125mg p.o. q12h; C: 500mg/125mg p.o. q8h (administration pre- and post-HD); D: 875mg/125mg p.o. q24h; E: 875mg/125mg p.o. q12h; F: 875mg/125mg p.o. q8h (administration pre- and post-HD); G: starting dose 1000mg/200mg iv, maintenance dose 500mg/100mg iv q24h; H: starting dose 1000mg/200mg iv, maintenance dose 500mg/100mg iv q12h; I: starting dose 1000mg/200mg iv, maintenance dose 500mg/100mg iv q8h; J: 1000mg/200mg iv q12h; K: 1000mg/200mg iv q8h.

CLA simulations showed only minor accumulation.



Contact

sunny.eloot@ugent.be

Universiteit Gent

@ugent

Ghent University